CJC-1295: The GHRH Receptor Analog in Growth Hormone Research

CJC-1295: The GHRH Receptor Analog in Growth Hormone Research

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) receptor analog based on the first 29 amino acids of human GHRH. With four D-amino acid substitutions at positions 2, 8, 15, and 27 for enhanced resistance to DPP-IV enzymatic degradation, it activates the GHRH receptor on anterior pituitary somatotroph cells to stimulate pulsatile growth hormone release.

The DAC vs. No-DAC Distinction

The version most commonly discussed in research is CJC-1295 without Drug Affinity Complex (DAC). The DAC is a chemical modification that binds the peptide to circulating albumin, extending its half-life from approximately 30 minutes to 6–8 days. The no-DAC version preserves the natural pulsatile pattern of GH release that is considered physiologically important for downstream IGF-1 signaling and receptor sensitivity.

The DAC version’s sustained, non-pulsatile GH elevation raises questions about potential impacts on GH receptor desensitization and negative feedback mechanisms. The no-DAC version avoids these concerns by matching the body’s natural release rhythm.

Comparison: CJC-1295 vs. Sermorelin vs. Tesamorelin

Sermorelin is unmodified GHRH(1-29) with no chemical protection from DPP-IV cleavage, giving it the shortest half-life (~10–15 minutes). Tesamorelin is a modified GHRH(1-44) analog with an N-terminal trans-3-hexenoyl group, previously approved as Egrifta® for HIV-associated lipodystrophy — the only GHRH analog with regulatory approval. CJC-1295 (no DAC) occupies the middle ground: more DPP-IV resistant than Sermorelin but without the sustained elevation concerns of the DAC version.

Mechanism: GHRH Receptor Activation

CJC-1295 binds to GHRH receptors (GHRHR) on somatotroph cells, activating the adenylyl cyclase / cAMP / PKA signaling cascade that triggers calcium-dependent exocytosis of stored growth hormone. The result is a dose-dependent GH pulse (2–10× baseline) that respects existing negative feedback loops — when GH and IGF-1 levels rise, somatostatin release suppresses further GHRH-mediated GH release.

Standalone Research Value

While frequently discussed alongside Ipamorelin, CJC-1295 has significant standalone research value. Studied independently, it provides clean data on GHRH receptor-specific effects without the confounding variable of ghrelin receptor co-activation. Applications include GHRH receptor pharmacology, GH pulsatility studies, age-related GH decline research, and metabolic pathway investigation.

The CJC-1295 + Ipamorelin Combination

The combination activates two distinct receptors on somatotroph cells: GHRHR (via cAMP/PKA) and GHS-R/ghrelin receptor (via IP3/calcium). This mechanistic synergy can produce larger GH pulses than either compound alone. However, the combination makes it challenging to isolate each peptide’s individual contribution to observed effects.

Disclaimer: This content is for informational and educational purposes only and is not medical advice. All compounds discussed are intended for research purposes only.